NKGen Biotech Company Executives
| NKGN Stock | 0.06 0.01 20.00% |
NKGen Biotech employs about 63 people. The company is managed by 9 executives with a total tenure of roughly 147 years, averaging almost 16.0 years of service per executive, having 7.0 employees per reported executive. Analysis of NKGen Biotech's management performance can provide insight into the firm performance.
| Paul MD CEO CEO Director |
NKGen |
NKGen Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (1.0685) % which means that it has lost $1.0685 on every $100 spent on assets. This is way below average. NKGen Biotech's management efficiency ratios could be used to measure how well NKGen Biotech manages its routine affairs as well as how well it operates its assets and liabilities.NKGen Biotech Common maintains a total of 44.95 Million outstanding shares. NKGen Biotech Common holds substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as NKGen Biotech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NKGen Biotech, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
NKGen Biotech Workforce Comparison
NKGen Biotech Common is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 126. NKGen Biotech totals roughly 63.0 in number of employees claiming about 50% of equities under Health Care industry.
NKGen Biotech Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NKGen Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on NKGen Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NKGen Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NKGen Biotech Notable Stakeholders
A NKGen Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NKGen Biotech often face trade-offs trying to please all of them. NKGen Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NKGen Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Paul MD | CEO Director | Profile | |
| Sangwoo Park | Executive Director | Profile | |
| Ryan CFA | SVP Strategy | Profile | |
| Yong Kim | Chief Officer | Profile | |
| Pierre Gagnon | Chief Officer | Profile | |
| CLS MBA | Vice Communications | Profile | |
| Irene Chang | Vice Resources | Profile | |
| James Graf | Interim Officer | Profile | |
| Yoonmi Kang | Vice Operations | Profile |
About NKGen Biotech Management Performance
The success or failure of an entity such as NKGen Biotech Common often depends on how effective the management is. NKGen Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NKGen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NKGen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NKGen Biotech Workforce Analysis
Traditionally, organizations such as NKGen Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NKGen Biotech within its industry.NKGen Biotech Manpower Efficiency
Return on NKGen Biotech Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 9.2M |
Other Information on Investing in NKGen Pink Sheet
NKGen Biotech financial ratios help investors to determine whether NKGen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NKGen with respect to the benefits of owning NKGen Biotech security.